Drug Discovery World

DECEMBER 7, 2022

Data analytics company Phesi analysed 2,358 clinical trials involving collagen. In the first 10 months of 2022, there were more than 225 new trials, compared with 125 in 2012. In 2021, the global collagen market was valued at $9.75 Phesi’s analysis shows that just 27% of trials received industry funding. billion by 2028.

Clinical Trials 130

Clinical Trials Trials Clinical Research Clinical Development 130

Drug Discovery World

MARCH 2, 2023

A rare disease is defined as a condition which affects less than one in 2000 people. million) in the UK being affected by a rare disease at some point in their lives. This has left many living with rare diseases without available or approved treatments and support for their conditions. This needs to change.

Drug Development 130

Drug Development Disease Clinical Trials Drugs 130

Drug Discovery World

OCTOBER 14, 2022

Cambridge Cognition has entered into an agreement to acquire eClinicalHealth Ltd (eCH), a full-service digital technology provider that is working on virtual clinical trials for three of the world’s top ten largest pharmaceutical companies. . The virtual clinical trial market . billion with a projected growth of 14% per annum 1.

Clinical Trials 130

Clinical Trials Trials Pharmaceutical Companies Pharmaceuticals 130

Drug Discovery World

DECEMBER 6, 2023

Gremlin 1 cells present opportunities for cartilage regeneration and their discovery will have relevance to other forms of cartilage injury and disease, which are notoriously challenging to repair and treat. Though this discovery is currently limited to animal models, human trials are underway.

Medical Schools 264

Medical Schools Clinical Trials Pharmaceuticals Trials 264

PPD

AUGUST 16, 2023

The COVID-19 pandemic rapidly accelerated the adoption of hybrid and decentralized clinical trial (DCT) models. However, as the world settles into its post-pandemic state and returns to pre-pandemic paradigms in many areas, the pharmaceutical industry remains dedicated to moving beyond traditional, centralized clinical trial constructs.

Clinical Trials 98

Clinical Trials Trials Clinical Research FDA 98

Drug Discovery World

FEBRUARY 21, 2024

In October 2023, pharmaceutical company NKGen Biotech released data from its Phase I clinical trial on the use of its investigational natural killer therapy, SNK01, to treat patients with Alzheimer’s disease. Why is this significant, and why are there currently no approved disease-modifying therapies for these patients?

Therapies 306

Therapies Trials Treatment Disease 306

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

Vial

MAY 13, 2024

However, progress from molecule to approved drug is hampered by extremely high costs and lengthy clinical trials , and approximately 90% of drugs that reach clinical trials fail. only 5% of molecules in oncology Phase I trials reach the market taking, on average, 7.5 In 2021, a review by Rennane et al.

Clinical Trials 52

Clinical Trials Trials Production Pharmacy 52

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.

Disease 49

Disease Pharmaceuticals Therapies Clinical Trials 49

The Pharma Data

AUGUST 30, 2021

Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments. Wilson disease. 1, 2, 3.

Disease 52

Disease Trials Therapies Treatment 52

Drug Discovery World

APRIL 18, 2024

First results from the EAGLE-1 Phase III trial for gepotidacin show that two oral doses of the antibiotic displayed superior success rates (92.6%) when compared to the combination treatment of ceftriaxone and oral azithromycin, which saw a 91.2% success rate.

Trials 130

Trials DNA Treatment Regulations 130

The Pharma Data

MAY 31, 2022

the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). Ph1 clinical trial is to evaluate the safety, tolerability, and?preliminary?efficacy?of of BRT-DA01 in patients with Parkinson’s disease.?. preliminary?efficacy?of

Trials 52

Trials Disease Clinical Trials Engineering 52

Drug Discovery World

DECEMBER 20, 2023

Centricity Research has acquired North Carolina-based Lucas Research, making it the fifth clinical research company to join Centricity since it launched in November 2021. With this acquisition, Centricity now has more than 35 clinical research sites, reaching 8.5 million geographically and ethnically-diverse patients.

Clinical Research 130

Clinical Research Research Clinical Trials Vaccine 130

Drug Discovery World

MARCH 1, 2024

Pepaxto associated with increased risk of death The FDA is alerting patients and health care professionals that a clinical trial (OCEAN, Study OP-103) evaluating Pepaxto with dexamethasone showed an increased risk of death. The FDA has now suspended enrolment in all ongoing Pepaxto clinical trials.

FDA 130

FDA Clinical Trials FDA Approval Trials 130

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

JANUARY 4, 2021

5, 2021 07:00 UTC. February 12, 2021. March 25, 2021. 2021 First Quarter Financial Update. April 21, 2021. 2021 Second Quarter Financial Update. July 21, 2021.

Clinical Trials 52

Clinical Trials Trials Treatment Disease 52

Drug Discovery World

JULY 11, 2023

Evotec and BMS aim to identify disease-modifying treatments for a broad range of neurodegenerative diseases. There is a significant unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases.

Licensing 189

Licensing Licensing Drugs Disease 189

Olympian Clinical Research

SEPTEMBER 16, 2022

million Americans were living with Alzheimer’s disease in 2021, according to the Centers for Disease Control and Prevention (CDC). Alzheimer’s disease is the seventh leading cause of death in the United States and is a devastating disease that can rob people of their memories and lives.

Disease 52

Disease Clinical Trials Clinical Research Trials 52

Drug Discovery World

APRIL 13, 2023

The R21/Matrix-M vaccine has demonstrated high levels of efficacy and safety in Phase II trials, including amongst children who received a booster dose of R21/Matrix-M at one year following a primary three-dose regime. This followed 2021 results from the Phase-IIb trial reporting that R21/Matrix-M demonstrated high-level efficacy of 77%.

Vaccine 246

Vaccine Clinical Trials Trials Production 246

The Pharma Data

MAY 17, 2021

The agency noted that master protocols can save drugmakers time and money in study startup and can accelerate drug development by evaluating multiple drugs at the same time and maximizing the amount of information gained during research, compared to stand-alone trials. Read the guidance here: www.fdanews.com/05-17-21-COVID-19.pdf.

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

JULY 29, 2021

econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We Second Quarter 2021 Financial Results. Total second quarter 2021 revenue of $6.2 As of June 30, 2021, Gilead had $7.4

Science 52

Science Production Treatment FDA 52

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. In 2021 there were an estimated 1.5

Research 130

Research Clinical Trials Therapies Clinical Development 130

The Pharma Data

JANUARY 12, 2021

12, 2021 — Drug maker Eli Lilly on Monday announced promising results from a small study of an experimental Alzheimer disease drug called donanemab. The two-year, phase 2 clinical trial included 272 patients with mild-to-moderate Alzheimer disease symptoms. © 2021 HealthDay. Posted: January 2021.

Disease 52

Disease Clinical Trials Drugs Trials 52

Drug Discovery World

DECEMBER 6, 2022

1 Vaccine development was conducted at great pace and within a year of the first infection being reported, the first Covid-19 vaccine to report phase III clinical trial data demonstrated unexpectedly high efficacy and cleared regulatory efficacy criteria with ease. Indeed, few randomised trials of NPIs have been undertaken.

Drug Development 246

Drug Development Vaccine Drugs Pharmaceuticals 246

The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research Government 52

The Pharma Data

APRIL 7, 2021

today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22. . Key AbbVie abstracts and presentation details for the 2021 AAN Annual Meeting program are outlined below. Clinical Trials Plenary Session.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

Drug Discovery World

SEPTEMBER 26, 2022

The approval by the European Commission was based on results from the Pathfinder clinical trial programme, which included the pivotal Navigator Phase III trial in which Tezspire demonstrated superiority across every primary and key secondary endpoint in patients with severe asthma, compared to placebo, when added to standard therapy.

Clinical Trials 130

Clinical Trials Trials Disease Production 130

The Pharma Data

JANUARY 12, 2021

The two-year, Phase 2 clinical trial included 272 patients with mild to moderate Alzheimer’s symptoms. After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques that are hallmarks of Alzheimer’s disease, according to Dr. Daniel Skovronsky, the company’s chief scientific officer.

Clinical Trials 52

Clinical Trials Laboratories Trials Treatment 52

Drug Discovery World

SEPTEMBER 6, 2022

Cell and gene therapies are not only transforming the way diseases are treated but are also aiming to cure entirely new patient populations. New applications and indications are being researched daily with the hope to address a wide array of rare and chronic diseases that have long been thought incurable. billion raised.

Therapies 130

Therapies Clinical Trials Production Disease 130

Chemical Biology and Drug Design

OCTOBER 10, 2023

Abstract Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. million people worldwide were living with HIV in 2021. Several agents are in clinical trials, including apricitabine, racivir, elvucitabine, doravirine, dapivirine, and elsulfavirine.

FDA Approval 100

FDA Approval Clinical Trials FDA Virus 100

The Pharma Data

FEBRUARY 8, 2021

PARIS – February 5, 2021 – Today, Sanofi holds a virtual investor event with key members of the Sanofi leadership team to share and discuss the overall progress in implementing the strategy in core parts of the business as well as the transformation of R&D. Key highlights to be presented at Capital Markets Day 2021.

Marketing 52

Marketing Clinical Trials Disease Vaccine 52

Drug Discovery World

FEBRUARY 1, 2023

billion in 2021 to just £1.8 Investment in UK biotech has fallen from £4.5 billion in 2022, mirroring the global economic downturn impacting all sectors. However, venture capital investment in the sector was the third-best year recorded for the UK, with £1.2 Leading UK biotechs also achieved pivotal milestones in their development.

Pharmaceutical Companies 244

Pharmaceutical Companies Science Marketing Pharmaceuticals 244

The Pharma Data

OCTOBER 28, 2021

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia®) clinical trial program, including the Phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)’s Kidney Week 2021 from 4-7 November.

Clinical Trials 52

Clinical Trials Trials Disease Hospitals 52

Drug Discovery World

SEPTEMBER 2, 2022

The CU School of Medicine was part of a multi-site clinical trial into the effectiveness of metformin, ivermectin and fluvoxamine in non-hospitalised adults with Covid-19. . The study, which launched in January 2021, included those who were vaccinated and those who were not, as well as people who were pregnant. Unusual remote study.

Drugs 243

Drugs Clinical Trials Trials Vaccine 243

The Pharma Data

JANUARY 11, 2021

In clinical trials, it could detect COVID-19 with 90%+ accuracy in about two minutes. . By the end of January, Johnson & Johnson is expected to deliver preliminary trial results for its one-dose COVID-19 vaccine candidate. . DalCor Pharmaceuticals initiated the Phase II dal-COVID trial of dalcetrapib for COVID-19.

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Disease 52

Disease Trials Treatment Clinical Trials 52

Drug Discovery World

AUGUST 21, 2023

Semaglutide manufacturer Novo Nordisk reported earlier this month that the drug reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity, as shown in the SELECT trial. However, these trials won’t be complete until 2026 at the earliest. It’s an exciting area,” he told The Guardian.

Clinical Trials 130

Clinical Trials Trials Treatment Licensing 130